Key result
ACE inhibitors and conventional antihypertensives delay end-stage renal failure and improve survival in IDDM nephropathy.
Why the study?
Do antihypertensive agents (ACE inhibitors, beta-blockers, diuretics) prevent or delay the progression of diabetic nephropathy in patients with diabetes mellitus?
Do antihypertensive agents (ACE inhibitors, beta-blockers, diuretics) prevent or delay the progression of diabetic nephropathy in patients with diabetes mellitus?
ACE inhibitors and conventional antihypertensive therapies are effective in slowing the progression of diabetic nephropathy and improving survival in patients with type 1 diabetes, though data in type 2 diabetes remains limited.
Answers are grounded in this paper and cite their sources.
Supports ACE inhibitor use in type 1 diabetic nephropathy; leaves open optimal regimens and efficacy in type 2 diabetes.
Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria (>300 mg/24 h), a relentless decline in glomerular filtration rate, and elevated systemic blood pressure. The prevalence of an abnormally elevated albumin excretion rate (>30 mg/24 h) is approximately 40% in patients with both insulin dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). Diabetes has become the leading cause of end-stage renal failure in the United States and Japan and it is still the second leading cause in Europe. Identification of patients at high risk of developing diabetic nephropathy is possible by screening for microalbuminuria (30 to 300 mg/24 h). Randomized controlled trials in normotensive IDDM and NIDDM patients with persistent microalbuminuria indicate that angiotensin-converting enzyme (ACE) inhibitors diminish urinary albumin excretion rate and postpone or may even prevent progression to clinically overt diabetic nephropathy. These findings suggest that screening and intervention programs are likely to have life-saving effects and lead to considerable economic savings. High blood pressure is an early and frequent phenomenon that can accelerate the course of diabetic nephropathy. Besides ACE inhibitors, conventional antihypertensive treatment (mainly P-blockers and diuretics) reportedly reduce albuminuria and diminish the loss of kidney function in IDDM patients with diabetic nephropathy. The same beneficial effect has been demonstrated using ACE inhibition combined with diuretics in hypertensive IDDM patients with overt nephropathy. Recently, a more beneficial effect of ACE inhibitors has been reported; the time to doubling of the baseline serum creatinine concentration was significantly prolonged in comparison with conventional antihypertensive treatment in IDDM patients with diabetic nephropathy and reduced kidney function (serum creatinine level>133 u.mol/L). Finally, it should be stressed that ACE inhibition and conventional antihypertensive treatment with p-blockers and diuretics postpone end-stage renal failure and improve survival in IDDM patients with diabetic nephropathy. Unfortunately, no information on these important issues is available in NIDDM patients with diabetic nephropathy
No takes yet. Share an insight, caveat, or question.
Parving et al. (1994) conducted a review in Diabetic nephropathy. Antihypertensive agents was evaluated. ACE inhibitors and conventional antihypertensive treatments postpone end-stage renal failure and improve survival in IDDM patients with diabetic nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: